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ABSTRACT 
Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model 
drug to produce sustained release tablets utilizing Compritol
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®
Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a 
powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The 
in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via 
differential scanning calorimetry.  
Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets 
prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80% at the 8-hour mark, whereas the 
tablets prepared by hot fusion method did not show such consistency. 
Conclusion: This study demonstrated the fact that Compritol
888 ATO as the retarding material and to study the influence of lipid: excipient ratio, 
excipient type as well as the processing conditions of the extruder on the release profile. 
®
Keywords: Theophylline, Hot-melt extrusion, Compritol
888 ATO is a suitable waxy material that can be used as a matrix-forming agent to 
control the release of theophylline using the Hot Melt Extrusion process.  
®
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Theophylline (1,3 dimethylxanthine) is a naturally occurring alkaloid, 
closely affiliated to caffeine. Its primary use is in the treatment of 
reversible airway obstruction and an adjunct to the therapy of left 
ventricular failure [1]. Sustained release of drugs alleviates the 
patient’s burden by reducing the dose frequency. Therefore, it is 
necessary to use dissolution methods during the development stage of 
oral SR tablets in order to allow pharmacokinetic screening, hence to 
predict the absorption rate and the bioavailability [2]. One of the main 
issues with the existing Theophylline sustained-release tablets is the 
difficulty to control the release rate of the drug. Moreover, the drug 
release rate is likely to differ between batches, and advanced 
technology is needed to ensure consistency among the tablets [3]. 
Drug absorption from a conventional matrix tablet is greatly affected 
by its transition rate in the gastrointestinal tract, and correspondingly, 
the bioavailability varies widely [4]. 
There are various methods to formulate sustained release tablets, 
such as Diffusion Sustained Release, Dissolution Sustained Release, 
pH-Dependent System, Altered Density System, Osmotic Pump 
System, Ion Exchange System [5]. The drug release from the 
undermentioned formulation might be attributed to the diffusion-
controlled mechanism.  
The choice of the matrix is essential because the matrix will regulate 
the drug release from the formulation and thereby sustain the 
therapeutic action over time [6]. Compritol®
Multiple methods have been employed to procure sustained-release 
dosage forms from glyceride-based formulations, i.e., thermoplastic 
or melt granulation [8], melt pelletization [9], hot-melt extrusion 
[10] and hot-melt coating [11]. In hot-melt extrusion technology 
process, polymer and excipients are conveyed by a rotating screw 
through a heated barrel of the extruder. The polymer melts at the 
high temperature, and the molten mass is incessantly pumped 
through the die connected at the end of the barrel. The molten 
polymer rapidly solidifies when the extrudate exits the machine 
through the die. When the shape of the die is changed, the final 
product may take the form of a film, pipe, tube, or granule [12]. 
Hot Melt Extrusion (HME) technology has numerous benefits which 
include the creation of unique dosage concepts, easily monitored 
which provide comprehensive documentation and simplifies quality 
control, continuous process with lower batch to batch variation, the 
potential for automation with reduction of capital investment and 
labor costs. Also, HME is an environmentally friendly process since the 
process does not require the use of solvents [13, 14]. Other than 
enhancing the bioavailability of a drug, the technique is useful to 
produce modified-release formulations with delayed drug delivery 
characteristics along with being capable of masking the taste, thus 
increasing the palatability [15]. 
The objective of the study was to formulate theophylline sustained-
release lipid matrices using the HME process and compare it with 
the hot fusion method. Compritol
888 ATO which consists 
of glyceryl behenate, a fatty acid ester of glycerol with an HLB of unit 
value, with low fusion point, has been employed as retard material 
for sustained-release dosage forms [7]. Glyceryl behenate is a waxy 
material, originally applied as a lubricant for tablets and is now 
widely used as a sustained-release excipient. 
®888 ATO was used as 
hydrophobic matrix base, and various distinct filters were 
incorporated to control the release rate. Six formulations were 
prepared by varying the composition and the technique (table 1). 
Theophylline was purchased from Yarrow Chem Products (Mumbai, 
India). Compritol®
For the preparation of formulations 1, 2 and 3 (table 1), 
Compritol
888 ATO, was generously supplied by Gattefossé 
(SAS,France), Avicel was a gift sample from Signet Chemical 
Corporation Pvt Ltd (Mumbai, India), Fujicalin and Lactose were 
obtained from Gangwal Chemicals Pvt Ltd (Bhiwandi, India) and 
Sisco Research Laboratories Pvt Ltd (Mumbai, India) respectively, 
and were used as received.  
The first 3 formulations were prepared using the hot fusion method. 
®888 ATO was melted in a china dish at 70 °C using a 
water bath. While maintaining the temperature, theophylline was 
added and mixed until a homogeneous dispersion was obtained. The 
mixture was cooled and passed through a mesh size 60 sieve. The 
excipients including Avicel/Fujicalin/lactose combination mixtures 
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were subsequently added, thoroughly mixed as per the ratios 
mentioned in table 1, and then compressed using Rimek Mini Press-I 
Multipunch automated machine to obtain 500 mg circular tablets.  
The latter 3 formulations were prepared using (HME). 
For formulations 4,5 and 6 (table1); Compritol®
Ingredients 
888 ATO and 
Theophylline were blended with the Avicel/Fujicalin/lactose 
combination mixtures prior to the extrusion process via the twin 
screw extruder (STEER-Omicron 10P, India) and were then 
subjected to a barrel temperature of 60 °C, 70 °C and 80 °C and 
screw speed rpm of 100. The external to internal screw diameter 
(Do/Di) ratio of the HME apparatus was 1.71. The powder thus 
obtained was passed through mesh size 60 sieve, the excipients 
were added, and the resulting mixture was compressed using Rimek 
Mini Press-I Multipunch automated machine to produce 500 mg 
circular tablets. 
  
Table1: Compositions for hot-fusion and HME process tablet formulations 
Hot fusion processed tablets Hot melt extrusion processed tablets 
1 2 3 4 5 6 
Theophylline (% w/w) 20 20 20 20 20 20 
Compritol®l888 ATO (%w/w) 15 15 15 15 15 15 
Avicel (%w/w) - - 32.25 - 32.25 - 
Fujicalin (%w/w) 64.5 32.25 32.25 64.5 32.25 32.25 
Lactose (%w/w) - 32.25 - - - 32.25 
Magnesium Stearate (%w/w) 0.5 0.5 0.5 0.5 0.5 0.5 
The rationale for implementing different formulation processes was to evaluate the effect on the theophylline dissolution patternswith respect to 
each other as well as against the marketed sustained release tablet. 
 
Characterization of formulation blends was performed, and the tapped 
density and bulk density was found to be in the range of 105 kgm-3 to 
250 kgm-3 and 80 kgm-3 to 200 kgm-3respectively. Compressibility index 
was ranging from 13.3% to 25.2% and the Hausner ratio varied from 
1.15 to 1.34; thus the flow character was found to lie between fair to 
good. The hardness of tablets was evaluated using a hardness tester 
(Electrolab Tablet Hardness Tester (model EH 01) 500N). The hardness 
did not change much with respect to the diluents, and it ranged from 5 
kgcm-2to6 kgcm-2for all the formulations. Thermal characteristics of 
extrudates were studied using differential scanning calorimetry (DSC) 
(DSC50, Shimadzu, Japan). The samples were heated from ambient 
temperature up to 300 °C under nitrogen atmosphere. As seen in fig. 1, 
the theophylline peak is observed at 282.36 °C indicating that the 
integrity of the base drug is not lost, along with revealing that it was 
found compatible with Compritol®888 ATO as well as the HME process. 
It can be deduced that neither of the components acted as an impurity 
towards the other indicated by the sharp endothermic peaks at around 
70 °C and 280 °C due to Compritol®
 
Fig. 1: DSC thermograms of theophylline with an extruded theophylline+compritol blend 
888 ATO and theophylline 
respectively. The integrity of the drug was thus shown to have been 
maintained. The absence of any peak at around 100 °C revealed the 




The in vitro dissolution studies of the formulations was performed 
using a dissolution tester USP (Electrolab TDT-08L) The USP 
Apparatus 2was adopted and paddles rotated at a speed of 50rpm 
throughout the study. The medium used for the dissolution of the 
Theophylline tablets was phosphate buffer of pH 7.2. The 
temperature of the water bath was maintained at 37 °C. 
Samples were withdrawn at predetermined time intervals and 
replaced with fresh buffer after each withdrawal. The dissolution was 
run for 8 h. The withdrawn samples were subjected to UV analysis at a 
wavelength of 273 nm (Shimadzu UV-1601PC UV-visible spectro-
photometer) to determine the content of Theophylline. 
The drug-release pattern with respect to time was studied between 
the tablets prepared by hot-fusion, by hot-melt extrusion and the 
marketed tablet of theophylline sustained release tablet. The results 
are depicted in fig. 2 and fig. 3. The marketed tablet of Theophylline 
showed an almost uniform release where the amount of 
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Theophylline released at the end of 8 h was seen to be less than 
30%. Among hot-fusion processed tablets, Formulation 1 and 2 had 
a comparable uniform release pattern with around 35% of drug 
released by the end of 2 h; while by the end of 8 h, more than 70% of 
Theophylline was released for the formulations 1 and 2. Formulation 
3 showed a high initial release of the drug reaching almost 70% by 
the end of 2 h. The release pattern leaned towards a ceiling effect 
after 6 h of dissolution reaching a peak release of 79% at 8 h. 
  
 




Fig. 3: Release pattern of tablets processed by HME method and the marketed sustained release tablet (results are expressed as 
mean±SD, n=3) 
 
As seen in fig. 3, in the formulations processed by HME method, the 
dissolution studies of all three formulations showed a similar 
pattern. Formulation 5 had a slightly faster release rate compared to 
the formulations 4 and 6 while formulation 4 had the highest 
percentage released at the end of 8 h. Formulation 4 had a sudden 
peak release between the 6th and 8th
Comparing the two methods of processing, it was observed by the 
dissolution studies using phosphate buffer pH 7.2, that the tablets 
prepared by HME method had a higher extent of release where all 3 
formulations crossed 80% at the 8-hour mark.  
 hour of the study. As shown by 
the results of the dissolution studies, the formulation containing 
64.25% of Fujicalin (formulation 4) showed the highest percentage 
of Theophylline released at the 8-hour mark, being the only 
formulation out of the 6to cross 90% of drug released. We can also 
deduce that formulation containing Avicel as excipient showed a 
faster release of the drug over the first 6 h compared to those devoid 
of that particular excipient. 
Previous researchers have attempted to formulate theophylline 
sustained-release tablets using ethylcellulose [16] and 
hydroxypropylcellulose [17] by direct compression. There is also 
mention of Eudragit RSPO matrix [18] and studies comparing 
different grades of hydroxypropyl methylcellulose and effects of 
polymer concentration on drug release profile [19]. Unlike previous 
polymers, which swell in water, and where the matrix ultimately 
disintegrates, the Compritol®888 ATO based inert matrices might 
provide another solution for the controlled release of those freely 
water-soluble drugs that require formulation into sustained or 
controlled drug release systems. Although it is hard to compare the 
results of different studies from the literature directly, the amount of 
Compritol®888 ATO employed in the matrix tablets in our study 
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(15% w/w) proved to be a sufficient amount to sustain theophylline 
release for more than 8 h. 
This study demonstrated the fact that Compritol®
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